Pain Medicine 207 2019 14181429 doi 101093pmpnz011 Advance Access Publication Date 8 March 2019 Original Research Article REHABILITATON SECTION Metaanalysis Comparing PlateletRich Plasma vs Hyaluronic Acid Injection Patients Knee Osteoarthritis Yanhong Han MDa Hetao Huang PhDa Jianke Pan PhDa Jiongtong Lin MD Lingfeng Zeng PhD Guihong Liang MD Weiyi Yang PhD Jun Liu PhD The Second Clinical College Guangzhou University Chinese Medicine Guangzhou China Department Orthopedics The Second Afﬁliated Hospital Guangzhou University Chinese Medicine Guangzhou China Bone Joint Research Team Degeneration Injury Guangdong Provincial Academy Chinese Medical Sciences Guangzhou China aEqual contribution Correspondence Jun Liu PhD The Second Afﬁliated Hospital Guangzhou University Chinese Medicine No 111 Dade Road Guangzhou China Tel 13149092114 fax 02081867705 Email liujun3040126com Funding sources This study supported National Ministry Industry State Health Planning Commission Orthopedic Surgery Robot Application Center construction projects No 2017MHDOSR1008 TCM Standardization Projects State Administration Traditional Chinese Medicine China No SATCM2015BZ115 No SATCM2015BZ173 Science Technology Planning Project Guangdong Province No 2012B061700037 No 2017ZC0185 Project Guangdong Provincial Department Finance No 2014157 No 20188 Medical Scientiﬁc Research Foundation Guangdong Province No A2017215 Science Technology Research Project Guangdong Provincial Hospital Chinese Medicine No YKYN2015MS15 Conﬂicts We declare conﬂicts Abstract Purpose The purpose metaanalysis compare plateletrich plasma PRP hyaluronic acid HA patients knee osteoarthritis KOA Methods Randomized controlled trials RCTs comparing use PRP HA KOA patients retrieved database establishment date April 2018 Outcome meas urements Western Ontario McMaster Universities Arthritis Index WOMAC visual analog scale VAS International Knee Documentation Committee Lequesne Index scores adverse events The pooled data evaluated Review Manager 535 Results Fifteen RCTs N ¼ 1314 included metaanalysis The present metaanalysis indicated PRP injections reduced pain effectively HA injections patients KOA 12 months followup evaluated WOMAC pain score VAS pain score showed signiﬁcant difference 12 months Moreover better functional improvement observed PRP group demonstrated WOMAC function score 12 months Additionally PRP injections dis play different adverse event rates compared HA injections Conclusion In terms longterm pain relief functional improvement PRP injections effective HA injections treatment KOA The opti mal dosage timing interval frequency injections ideal treatment different stages KOA main areas concern future investigations Key Words PlateletRich Plasma Osteoarthritis Knee Hyaluronic Acid Randomized Controlled Trials Randomized Control Trials Metaanalysis Introduction Knee osteoarthritis KOA progressive joint disease involves intra periarticular structures 1 considered pathology characterized articu lar cartilage lesions synovitis subchondral sclerosis osteophytes 2 In addition KOA common causes joint pain loss motor function middleaged elderly people United States 34 Despite advances medical tech intervention currently nology drug surgical VC 2019 American Academy Pain Medicine This Open Access article distributed terms Creative Commons Attribution NonCommercial Licensehttpcreativecommonsorglicensesbync40 permits noncommercial reuse distribution reproduction medium provided original work properly cited For commercial reuse contactjournalspermissionsoupcom 1418 Metaanalysis Comparing PlateletRich Plasma vs Hyaluronic Acid Injection 1419 available delaying development KOA 5 topical Oral antiinflammatory drugs physiotherapy antiinflammatory gels intraarticular injections currently routine treatments patients symp tomatic KOA 56 Nonsurgical treatments ex loss recommended ercise weight surgical treatment lead increased symptoms poor functional outcomes 7 However compliance nonsurgical treatment lower KOA medi cations simple analgesics nonsteroidal antiinflammatory drugs associated ad verse events 89 Many studies reported hy aluronic acid HA viscoinduction properties increase intraarticular lubrication intra articular HA injection widely treat KOA 10 However intraarticular drug therapy associated reduced pain increased joint function patients effective patients KOA 11 The 1314 structure intraosseous subchondral treat knee osteoarthritis In past decade use autologous growth factors intra articular injection plateletrich plasma PRP ceived increasing attention 12 Recent studies demonstrated growth factors cytokines released platelets injury modulate flammatory process help maintain regenerate tis bone sue contributes cartilage repair process KOA PRP autologous blood product containing high concentration platelets emerg ing treatment ligament tendon cartilage bone injuries orthopedics sports medicine 1518 The intraarticular injection PRP minimally vasive treatment widely treatment 19 clinically related diseases Sanchez et al reported new technique delivery PRP infiltration combined intra articular injections treat severe KOA adverse reactions occurred study Many clinical studies reported good clinical efficacy PRP injections 2022 previously published sys tematic reviews metaanalyses suggested PRP safe effective orthopedic treatment compared intraarticular injections 2327 However reviews reach consensus terms effects PRP pain relief functional recovery concluded highquality random ized controlled trials RCTs needed Previous reviews included nonRCTs analyzed small number RCTs 10 additional random ized trials published Therefore systematic reviews metaanalyses needed fully investigate effects PRP knee pain relief functional improvement Our aim identify prospective RCTs published date provide upto date insights efficacy PRP treatment KOA Methods According PRISMA criteria created prospec tive protocol including search strategies selection crite ria outcome measurements methods statistical analysis commencing study The study ap proved Ethics Committee Second Affiliated Hospital Guangzhou University Chinese Medicine This PROSPERO registered CRD42018108825 review Search Strategy A comprehensive search PubMed 1966April 2018 EMBASE 1980April 2018 Cochrane li brary 1966April 2018 databases conducted The search terms included plateletrich plasma PRP knee osteoarthritis arthritis arthritic No language exclusions applied Manual searches performed references identified studies Selection Criteria The inclusion criteria follows 1 RCTs compar ing PRP HA treatment patients KOA 2 data include key outcome indica including Western Ontario McMaster tor Universities Arthritis Index WOMAC International Knee Documentation Committee IDKC visual analog scale VAS Lequesne Index adverse events The exclusion criteria follows 1 retrospective studies cohort studies nonrandomized studies 2 case reports letters editorials animal experimental stud ies 3 inability extract relevant data cluded studies Data Extraction Two authors YHH HTH independently extracted relevant data included studies including authors names publication date patient age gender patient body mass index BMI sample size radiographic classification followup period details PRP treatment protocols controls related clinical results In event data missing obtained detailed infor mation contacting appropriate author Quality Assessment Two authors YHH JKP independently assessed methodological quality included studies Cochrane Collaboration Tool assessing risk bias ROB Each included study scored having high low unclear ROB according following evaluation criteria 1 random sequence generation 2 al location concealment 3 blinding participants personnel 4 blinding outcome assessments 5 incom plete outcome data 6 selective reporting 7 sources bias Any discrepancies reviewers findings arbitrated appropriate senior experts 1420 Han et al 535 software Statistical Analysis Cochrane Review Manager Collaboration Oxford UK analyses Continuous data metaanalysis calculated expressed mean differences MDs 95 confidence intervals CIs dichotomous data metaanalysis presented risk ratios RRs 95 CIs Heterogeneity studies esti mated I2 test If heterogeneity I2 value 75 higher randomeffects model fixedeffects model P values 005 considered indicate statistical significance results Ethical Approval This article contain studies human par ticipants animals performed authors Results Search Results Figure 1 shows flow diagram study selection A tal 586 records identified initial litera ture search Of 296 records excluded thorough screen titles abstracts Ultimately remaining 51 studies assessed performing fulltext review 15 RCTs 221222839 cluded metaanalysis Study Characteristics Table 1 shows characteristics included studies The sample sizes studies ranged 10 94 total 1314 individuals 643 individuals cluded HA group 671 individuals PRP group One studies 28 total followup pe riod months seven studies 293034353739 followup periods studies 2122313336 followup periods 12 months study 2 followup period 18 months With exception study 37 studies Kellgren Lawrence grading scales classify severity KOA The patients studies KOA severity class II III The demographic characteristics groups cluded studies similar months The preparation administration PRP varied studies Table 2 shows details PRP preparation administration protocols specific included study PRP category use exog enous activators injection regimen including doses times intervals Assessment ROB The summary ROB assessment included studies illustrated Figure 2 Adequate randomized sequences generated 13 studies 2192228 Figure 1 Flow diagram study selection 3139 However studies 2930 referred random assignments report details random assignments Appropriate allocation concealment reported studies 2122283133343739 blinding participants personnel clear studies 2122283133343739 blinding outcome studies 212233353739 Incomplete outcome data observed included studies In addition selective reporting obvious sources bias identified studies reported assessors Outcomes Metaanalysis WOMAC Pain Score WOMAC pain scores reported 23132 2313239 22131323738 stud ies 221313236 12 months spectively The pooled analysis reveal significant differences PRP HA groups MD ¼ cid2019 95 CI ¼ cid2065 027 I2 ¼ 67 P ¼ 042 months MD ¼ cid2031 95 CI ¼ cid2116 054 I2 ¼ 88 P ¼ 047 However subjects PRP group experienced significantly pain relief HA group MD ¼ cid2124 95 CI ¼ 194 cid2053 I2 ¼ 83 P ¼ 00006 12 months Metaanalysis Comparing PlateletRich Plasma vs Hyaluronic Acid Injection 1421 s t n e v e e s r e v d A C A M O W C K D I C A M O W S A V C A M O W S A V s t n e v e e s r e v d A S A V C K D I C A M O W x e d n I e n s e u q e L s t n e v e e s r e v d A s t n e v e e s r e v d A C K D I C K D I s t n e v e e s r e v d A x e d n I s t n e v e e s r e v d A x e d n I e s r e v d A C A M O W S A V e n s e u q e L C A M O W e n s e u q e L C A M O W C A M O W e s r e v d A C A M O W S A V s t n e v e s t n e v e C K D I e s r e v d A C A M O W S A V s t n e v e 3 6 6 2 1 2 1 2 1 6 6 6 2 1 2 1 6 8 1 6 2 1 s e m o c t u O l c n l C o m s d o r e P p u w o l l o F V I I I I I I I V I I I I I I I A H I I I I I P R P I I I I I L K n o t c f s s l C c h p r g o d R 6 5 6 8 0 3 9 8 2 cid3 6 7 1 9 1 1 6 9 7 2 5 9 2 cid3 4 9 1 3 0 1 6 7 2 5 7 3 1 6 9 9 4 6 7 cid3 9 3 6 7 cid3 6 3 3 7 8 7 3 8 9 6 2 m g k I M B y e g A M F r e d n e G e z S e l p m S A H P R P A H P R P A H P R P A H P R P e t D r o h t u A s e d u t s d e d u l c n e h t f o s c t s r e t c r h C 1 e l b T V I I I I I I I I I I I I I I I I I I I V I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I A N 4 6 6 0 9 2 6 3 6 4 8 2 4 4 6 9 6 2 7 3 6 7 9 2 9 4 6 4 0 3 A N 9 3 6 4 7 2 6 4 6 6 7 2 0 4 6 6 6 2 8 4 6 7 8 2 5 5 6 0 9 2 6 0 1 6 2 6 6 5 0 1 6 8 6 5 1 9 6 3 0 6 8 1 1 6 6 7 5 4 1 6 5 3 5 6 8 6 5 1 6 3 1 1 6 5 6 6 4 0 1 6 9 5 5 1 5 6 4 0 6 2 3 1 6 3 3 5 1 3 1 6 3 7 5 3 8 6 3 6 6 V I I I I I I I V I I I I I I I A N A N 2 4 6 0 7 2 7 2 6 2 8 2 6 4 6 2 8 2 9 2 6 9 7 2 5 7 6 1 1 6 2 8 6 9 8 5 1 9 6 9 6 5 9 7 6 5 0 6 2 3 8 2 0 3 0 2 1 3 3 2 5 7 3 7 1 2 2 9 7 1 5 1 7 4 9 2 5 4 5 3 5 2 1 2 8 2 1 2 3 0 6 4 3 6 1 3 2 2 1 5 1 8 9 6 3 3 6 4 V I I I I I I V I I I I I I 6 4 6 0 1 3 6 3 6 7 0 3 7 7 6 8 4 6 6 6 6 4 2 6 6 1 6 2 6 1 2 3 I I I I I I I I I I I I I I I 9 2 6 5 7 2 2 8 2 6 6 8 2 5 7 6 5 9 5 2 7 6 0 7 5 6 7 2 7 9 2 I I I I I 1 1 6 7 8 2 4 1 6 2 8 2 4 6 6 1 3 5 6 6 6 2 4 5 2 1 8 1 1 1 4 1 I I I I I I V I I I I I I I I I I V I I I I 6 2 7 2 8 5 5 5 9 2 6 0 7 2 9 2 6 6 5 2 5 1 1 6 5 8 4 7 1 1 6 2 3 5 1 3 4 2 1 1 3 1 7 3 7 1 4 1 0 1 0 1 5 1 0 6 0 5 4 3 9 8 9 3 6 2 2 6 4 7 2 4 3 3 0 3 5 5 4 2 1 1 5 1 0 6 9 4 3 3 4 9 9 3 7 2 7 7 9 7 8 4 6 3 5 2 4 5 4 2 6 1 0 2 1 1 0 2 8 2 l t e n o s r e t P 9 2 l t e L 2 1 0 2 7 1 0 2 6 1 0 2 5 1 0 2 5 1 0 2 6 1 0 2 5 1 0 2 2 1 0 2 2 3 l t e s u m y u D 3 3 l t e o d r l F 4 3 l t e l e m r o G d e r e H z e n t n o M 0 3 l t e z r e C 1 3 l t e e l o C 5 3 l t e 6 3 l t e t d s s e R 7 3 l t e z e h c n S 3 1 0 2 1 2 l t e o z r e u q V 7 1 0 2 8 3 l t e t d s s e R 8 1 0 2 2 1 0 2 8 1 0 2 2 2 l t e o d r l F 9 3 l t e s u o L 2 l t e u S l u s v ¼ S A V m s l p h c r t e l e t l p ¼ P R P e l b l v t o n t d ¼ A N e l c s g n d r g e c n e r w L d n n e r g l l e K ¼ L K e e t t m m o C n o t t n e m u c o D e e n K l n o t n r e t n I ¼ C K D I d c c n o r u l y h ¼ A H x e d n s s m y d o b ¼ I M B x e d n I s t r h t r A s e t s r e v n U r e t s M M d n o r t n O n r e t s e c W ¼ C A M O W e l c s g o l n 1422 Han et al Table 2 Details PRP treatment protocols controls PRP Author Date Category Activation Paterson et al 28 Li et al 29 Cerza et al 30 Cole et al 31 Duymus et al 32 Filardo et al 33 PAPRP 2016 2011 PRP 2012 ACP PRP 2017 PRP 2016 PRP 2015 Gormeli et al 34 2015 PRP Ultraviolet light Calcium chloride NA NA NO 10 calcium chloride 1 mL calcium chloride Injection Dose Times Intervals Fresh Frozen 3 mL 3 times weekly 35 mL 3 times 3 weeks 55 mL 4 times weekly 4 mL 3 times weekly 5 mL 2 times monthly 5 mL 3 times weekly Fresh Fresh Fresh Fresh Fresh Fresh HA Type Injection Dose Times Intervals Hylan GF 20 Sofast Hyalgan Hylan GF 20 Ostenil Plus Hyalubrix 3 mL 3 times weekly 2 mL 3 times 3 weeks 20 mg 4 times weekly 16 mg 3 times weekly 40 mg 1 time monthly 30 mg 3 times weekly 5 mL 3 times weekly 1 fresh Orthovisc 2 mL 3 times weekly 2 frozen MontanezHeredia 2016 PRP NA NA 3 times 15 days Frozen Adant NA 3 times 15 days et al 35 Raeissadat et al 36 Sanchez et al 37 2015 2012 LRPRP PRGF NO 400 uL calcium 46 mL 2 times 4 weeks 8 mL 3 times weekly Fresh Fresh Hyalgan Euﬂexxa 20 mg 3 times weekly NA 3 times weekly chloride Vaquerizo et al 21 2013 PRGF 400 uL calcium 8 mL 3 times weekly Fresh Durolane NA 1 time chloride Raeissadat et al 38 Su et al 2 Filardo et al 22 Louis et al 39 2017 2018 2012 2018 PRGF LRPRP PRP PRP 15 mL Rooyagen Calcium chloride NA Calcium chloride 5 mL 2 times 3 weeks 6 mL 2 times 14 days 5 mL 3 times weekly 3 mL 1 time Fresh Fresh Frozen Fresh Hyalgan Freda Hyalubrix Durolane 20 mg 3 times weekly 2 mL 5 times weekly NA 3 times weekly 3 mL 1 time ACP ¼ autologous conditioned plasma HA ¼ hyaluronic acid LPPRP ¼ leukocytepoor plateletrich PRP LRPRP ¼ leukocyterich plateletrich PRP NA ¼ data available NO ¼ No Activation PAPRP ¼ photoactivation plateletrich plasma PRGF ¼ plasma rich growth factors PRP ¼ plateletrich plasma Random sequence generation selection bias Allocation concealment selection bias Blinding participants personnel performance bias Blinding outcome assessment detection bias Incomplete outcome data attrition bias Selective reporting reporting bias Other bias Low risk bias Unclear risk bias High risk bias 0 25 50 75 100 Figure 2 Risk bias assessment MD ¼ cid2175 95 CI ¼ cid2250 cid2101 I2 ¼ 89 P 0000001 Table 3 presents details 12 months MD ¼ cid2099 95 CI ¼ cid2157 cid2042 I2 ¼ 81 P ¼ 00007 Table 3 presents details WOMAC Stiffness Score WOMAC stiffness scores reported 232 23239 221323738 studies 2213236 12 months respectively The pooled analysis reveal significant differences PRP HA groups MD ¼ cid2013 95 CI ¼ cid2041 015 I2 ¼ 35 P ¼ 037 months MD ¼ cid2046 95 CI ¼ cid2092 001 I2 ¼ 60 P ¼ 005 However subjects PRP group experienced significantly greater improvement knee stiff ness HA group MD ¼ 035 95 CI ¼ cid2063 cid2008 I2 ¼ 0 P ¼ 001 WOMAC Function Score WOMAC function scores reported 232 23239 221323738 studies 2213236 12 months respec tively The pooled analysis showed subjects PRP HA groups exhibited similar functional recovery month MD ¼ cid2235 95 CI ¼ cid2528 057 I2 ¼ 59 P ¼ 012 treatment However sub jects PRP group performed better HA group MD ¼ cid2192 95 CI ¼ cid2257 cid2127 I2 ¼ 0 P 0000001 MD ¼ cid2371 95 CI ¼ cid2721 cid2022 I2 ¼ 84 P ¼ 004 Metaanalysis Comparing PlateletRich Plasma vs Hyaluronic Acid Injection 1423 P Value Effect Size Z P 080 042 089 037 157 012 179 007 072 047 250 001 582 0000001 170 009 342 00006 193 005 208 004 313 0002 461 0000001 340 00007 295 0003 293 0003 Table 3 Details PRP treatment protocols control Followup mo WOMAC No Studies No Cases PRPHA MD 95 CI Heterogeneity P I2 1 3 6 12 Pain Stiffness Function Total Pain Stiffness Function Total Pain Stiffness Function Total Pain Stiffness Function Total 3 2 2 3 4 3 4 5 6 5 5 7 5 4 4 4 108114 5864 5864 119124 129138 8088 8088 155163 270263 221213 221213 296288 232218 183168 183168 183168 PRP HA Total SD SD Total Mean Mean Study Subgroup 111 1 month Duymus 2016 Paterson 2016 Su 2018 Subtotal 95 CI Heterogeneity Tau² 000 Chi² 117 df 2 P 056 I² 0 Test overall effect Z 014 P 089 12 1406 035 07 1761 019 25 1964 346 26 129 344 33 11 25 69 34 10 30 74 112 3 months 34 Duymus 2016 Louis 2018 24 Paterson 2016 9 Su 2018 24 Subtotal 95 CI 91 Heterogeneity Tau² 009 Chi² 714 df 3 P 007 I² 58 Test overall effect Z 088 P 038 29 34 3689 3 07 26 2542 027 31 36 1413 323 09 3 93 031 33 22 10 24 89 cid2013 cid2235 cid2381 cid2031 cid2035 cid2192 cid2502 cid2124 cid2046 cid2371 cid21078 cid2175 cid2099 cid2890 cid21211 Weight 88 00 912 1000 065 027 041 015 528 057 798 036 116 054 063 cid2008 257 cid2127 1079 076 194 cid2053 092 001 721 cid2022 1751 cid2404 250 cid2101 157 cid2042 1482 cid2299 2021 cid2401 005 67 021 35 012 59 003 71 00001 88 044 0 080 0 000001 89 00001 83 004 60 00001 84 000001 94 000001 89 0001 81 000001 94 000001 94 Mean Difference IV Random 95 CI Mean Difference IV Random 95 CI 010 057 037 674 683 2031 002 013 017 001 013 015 401 66 01 532 1000 020 059 019 020 182 142 2276 587 3965 023 039 007 020 064 024 113 6 months Cole 2017 Duymus 2016 Raeissadat 2017 Su 2018 Subtotal 95 CI Heterogeneity Tau² 1540 Chi² 37873 df 3 P 000001 I² 99 Test overall effect Z 183 P 007 50 34 33 30 147 49 33 36 25 143 246 252 248 254 1000 346 4 46 426 324 13 278 035 37 13 239 064 486 43 48 444 114 12 months Cole 2017 Duymus 2016 Su 2018 Subtotal 95 CI Heterogeneity Tau² 626 Chi² 23416 df 2 P 000001 I² 99 Test overall effect Z 336 P 00008 49 33 25 107 50 34 30 114 44 51 478 46 13 019 38 01 038 573 68 545 311 343 346 1000 1400 1537 1263 030 092 032 020 142 102 018 045 009 362 749 026 1330 1496 1164 170 214 126 067 083 051 495 783 206 Test subgroup differences Chi² 1532 df 3 P 0002 I² 804 Figure 3 Forest plot metaanalysis VAS score 4 0 Favours PRP Favours HA 2 2 4 12 months MD ¼ cid2890 95 CI ¼ cid21482 cid2299 I2 ¼ 94 P ¼ 0003 Table 3 presents details WOMAC Total Score WOMAC total scores reported 23032 229303239 seven 2212930323738 studies 2213236 12 months respectively The pooled analysis identify signifi differences PRP HA groups MD ¼ cid2381 95 CI ¼ cid2798 036 I2 ¼ 71 P ¼ 007 months MD ¼ cid2502 95 CI ¼ cid21079 076 I2 ¼ 89 P ¼ 009 However sub jects PRP group experienced significantly greater im provement total scores HA group 1424 Han et al PRP SD HA SD Total Mean Mean Study Subgroup 311 2 months Filardo 2012 Filardo 2015 Subtotal 95 CI Heterogeneity Tau² 000 Chi² 018 df 1 P 067 I² 0 Test overall effect Z 015 P 088 55 94 149 54 89 143 176 166 614 635 162 152 628 632 Total Weight 345 655 1000 312 6 months Cole 2017 Filardo 2012 Filardo 2015 Gormeli 2015 Li 2012 Subtotal 95 CI Heterogeneity Tau² 1327 Chi² 1711 df 4 P 0002 I² 77 Test overall effect Z 404 P 00001 49 55 94 39 15 252 50 54 89 39 15 247 36 164 161 98 135 558 61 635 484 632 38 182 171 62 119 655 643 65 608 764 285 162 204 236 113 1000 313 12 months Cole 2017 Filardo 2012 Filardo 2015 Subtotal 95 CI Heterogeneity Tau² 3128 Chi² 1553 df 2 P 00004 I² 87 Test overall effect Z 166 P 010 49 55 94 198 50 54 89 193 388 286 326 1000 376 19 18 466 617 642 337 168 167 576 649 662 Mean Difference IV Random 95 CI Mean Difference IV Random 95 CI 140 495 775 030 491 431 029 344 402 970 824 1116 330 321 981 150 332 632 1240 876 1604 1320 409 2231 802 413 1191 1100 959 1241 320 354 994 200 304 704 584 105 1272 Test subgroup differences Chi² 815 df 2 P 002 I² 755 Figure 4 Forest plot metaanalysis IDKC 10 5 0 Favours HA Favours PRP 5 Study Subgroup Li 2012 Sanchez 2012 Vaquerizo 2013 PRP SD 1 34 34 Mean 31 52 52 Total 15 79 48 Mean 66 54 54 HA SD 21 33 33 Total 15 74 42 Weight 335 341 323 Mean Difference IV Random 95 CI 350 468 232 020 126 086 020 159 119 Mean Difference IV Random 95 CI Total 95 CI 1000 Heterogeneity Tau² 337 Chi² 1996 df 2 P 00001 I² 90 Test overall effect Z 117 P 024 142 131 131 350 089 4 2 0 Favours PRP Favours HA 2 10 4 Figure 5 Forest plot metaanalysis Lequesne index scores MD ¼ cid21078 95 CI ¼ cid21751 cid2404 I2 ¼ 94 P ¼ 0002 12 months MD ¼ cid21211 95 CI ¼ cid22021 cid2401 I2 ¼ 94 P ¼ 0003 All details presented Table 3 2313238 VAS VAS scores pain reported 2832 2283239 studies 23132 12 months respectively Therefore subgroup metaanalysis performed compare VAS scores pain based length followup No significant differences observed tween PRP HA groups MD ¼ 001 95 CI ¼ cid2013 015 I2 ¼ 0 P ¼ 089 MD ¼ cid2020 95 CI ¼ cid2064 024 I2 ¼ 58 P ¼ 038 months MD ¼ cid2362 95 CI ¼ cid2749 026 I2 ¼ 99 P ¼ 007 However treatment PRP groups exhibited better efficacy HA groups 12 months MD ¼ cid2495 95 CI ¼ cid2783 cid2206 I2 ¼ 99 P ¼ 00008 Figure 3 IDKC IDKC scores reported 2233 2229313334 studies 223133 12 months respectively Therefore subgroup metaanalysis performed compare IDKC scores based length followup No significant differences observed PRP HA groups MD ¼ 029 95 CI ¼ cid2344 402 I2 ¼ 0 P ¼ 088 12 months MD ¼ 584 95 CI ¼ cid2105 1272 I2 ¼ 87 P ¼ 010 However sub jects PRP group significantly better IDKC scores HA group months MD ¼ 802 95 CI ¼ 413 1191 I2 ¼ 77 P 00001 Figure 4 Lequesne Index Lequesne Index scores reported studies 212937 142 patients treated PRP 131 HA The pooled analysis reveal significant difference PRP HA groups months MD ¼ cid2131 95 CI ¼ cid2350 089 I2 ¼ 90 P ¼ 024 Figure 5 Metaanalysis Comparing PlateletRich Plasma vs Hyaluronic Acid Injection 1425 Study Subgroup Cerza 2012 Filardo 2012 Li 2012 Louis 2018 MontanezHeredia 2016 Paterson 2016 Sanchez 2012 Su 2018 Vaquerizo 2013 PRP Events 0 7 12 1 9 2 26 8 7 Total 60 36 15 22 28 10 79 25 48 AH Events 0 2 12 2 4 0 24 5 9 Total 60 33 15 24 27 9 74 30 42 Weight 35 202 32 68 09 416 76 161 oitaR ksiR MH Fixed 95 CI Not estimable 321 072 1436 100 070 143 055 005 560 217 076 622 455 025 8370 101 064 160 192 072 513 068 028 167 oitaR ksiR MH Fixed 95 CI Total 95 CI Total events Heterogeneity Chi² 804 df 7 P 033 I² 13 Test overall effect Z 128 P 020 323 58 72 314 1000 120 091 158 001 01 10 1 Favours PRP Favours HA 100 Figure 6 Forest plot metaanalysis adverse events Adverse Events Adverse events reported studies 22128 30353739 323 patients treated PRP 314 HA The pooled analysis detect signif icant difference PRP HA groups RR ¼ 120 95 CI ¼ 091 158 I2 ¼ 13 P ¼ 020 Figure 6 Discussion As common degenerative joint disease KOA sec ond leading cause loss joint function 4 causes enormous economic social burdens world wide 40 The understanding KOA terms etiol ogy pathogenesis remains unclear 41 main pathological changes involve components joints degeneration articular cartilage 42 HA mainly composed important factors Dglucosamine NacetylDglucosamine factors play important role nourishing cartilage protecting joints 43 HA degraded diluted exudates resulting decrease molecular weight endogenous concentration HA knee joint cavity patients KOA These changes reduce viscoelasticity knee cartilage reduce knees ability resist mechanical stress damage 1144 Many clinical studies shown HA effec tively relieve knee pain improve knee function 45 47 However researchers shown HA improve regeneration damaged cartilage par ticularly elderly patients severe KOA 4448 PRP highly concentrated autologous plasma containing variety growth factors promote healing ligaments tendons bones including plateletderived growth factor transforming growth factorb vascular endothelial growth factor basic fibroblast growth factor bioactive proteins 4951 As vector large growth factors 52 PRP promotes tissue repair 53 increasingly treat KOA PRP plays impor tant role mesenchymal stem cell proliferation car tilage formation combination growth factors 54 It reported PRP positive effect inducing migration prolifera tion differentiation precursor cells cartilage Therefore PRP effectively repair damaged carti lage knee joint 55 reducing effects knee pain inflammatory responses 56 These effects PRP new drug treatment KOA Most previous systematic reviews shown PRP effective alternative treatment long term relief knee pain improved joint function KOA patients However previous conclusions reached basis small number RCTs 23 262757 time effect PRP injection ther apy KOA fully investigated Chang et al 58 patients receiving PRP injections showed better longerlasting improvements patients receiv ing HA treatment studies included analysis case series RCTs Laudy et al 27 pooled 10 trials including RCTs PRP injections effec tive placebo HA injections alleviating pain symptoms improving joint motor function KOA patients Another recent metaanalysis 11 included 13 studies 10 RCTs synthesized WOMAC scores compare efficacy PRP injections HA injections Based large number RCTs study evaluated effects PRP treatment knee joint pain physiological function different times injection In study data 15 RCTs showed longterm pain relief functional improvement PRP group superior HA group Divergent results observed WOMAC VAS IKDC Lequesne Index scores oc currence adverse events The principal findings study months postinjection subjects PRP group HA group similar experiences respect pain relief WOMAC pain score VAS pain score functional improvement WOMAC total score WOMAC function score IKDC score In addition significant differences 1426 Han et al Lequesne Index observed PRP HA groups months However subjects PRP group experienced significantly better pain relief WOMAC pain score VAS pain score func tional improvement WOMAC function score WOMAC total score IKDC score 12 months postinjection HA group In addition HA PRP groups display different adverse event rates Heterogeneity different measured parameters indicating effects inconsistent studies Based careful review evaluation included studies com mon problems First pathology KOA PRP HA groups different included studies distribution KOA severity studies varied grades I IV KL grading scale As shown studies Chang et al 58 Filardo et al 59 PRP better effect patients early moderate forms KOA limited effect patients advanced forms KOA Therefore patients different stages KOA exhibit responses PRP HA treatment 11 Additionally number injections length time injections varied included studies Among studies cluded multiple injections interval weeks studies MontanezHeredia et al 35 Su et al 2 weeks adopted Li et al 29 Raeissadat et al 38 month adopted Duymus et al 32 Raeissadat et al 36 In study Gormeli et al 34 differences ob served patients received HA injection received singledose PRP injection patients receiving multipledose PRP experi enced greater improvement patients receiving ei ther treatments However Patel et al 53 concluded single dose PRP injection double dose PRP injection therapeutic ef fect The study Go rmeli et al 34 confirmed conclusion patients advanced KOA difference treatment methods These findings provide guidance future treatment options consensus treatment meth ods currently unavailable As study systematic review inevitably certain limitations Limitations exist recom mendation routine PRP injections treatment KOA composition PRP remains uncertain Different types PRP preparations preparations differ platelet counts growth factor concentrations leukocyte counts depending patient characteristics preparation kit Furthermore interval injections op timal dosage areas concern future cause exert effect postinjection process currently published studies supporting specific injection protocol In present study insufficient data available conduct subgroup analysis confirm multiple injections necessary patients different stages KOA Conclusions Based current evidence use PRP treat KOA positive effect pain levels functional outcomes In addition PRP injections display dif ferent adverse event rates compared HA injections There lack clarity number fre quency PRP injections required achieve maximum results ideal treatment regimens different severities KOA Authors Contributions Conceived designed experiments Yanhong Han Jun Liu performed experiments Jianke Pan Weiyi Yang Lingfeng Zeng analyzed data Hetao Huang Jiongtong Lin Guihong Liang wrote paper Yanhong Han Jianke Pan Acknowledgments We grateful American Journal Experts language assistance process writing manuscript References 1 Lane NE Brandt K Hawker G et al OARSIFDA initiative Deﬁning disease state osteoarthritis Osteoarthritis Cartilage 201119547882 2 Su K Bai Y Wang J et al Comparison hyaluronic acid PRP intraarticular injection combined intraarticular intraosseous PRP injections treat osteoarthritis Clin knee Rheumatol 2018375134150 patients 3 Suri P Morgenroth DC Hunter DJ Epidemiology osteoarthritis associated comorbidities Pm R 201245 SupplS109 4 Lawrence RC Felson DT Helmick CG et al Estimates prevalence arthritis rheumatic conditions United States Part II Arthritis Rheumatism 20085812635 5 Zhang W Moskowitz RW Nuki G et al OARSI rec ommendations management hip knee osteoarthritis Part II OARSI evidencebased expert consensus guidelines Osteoarthr Cartilage 200816 213762 6 Pham T Maillefert JF Hudry C et al Laterally ele vated wedged insoles treatment medial knee osteoarthritis A twoyear prospective randomized controlled study Osteoarthritis Cartilage 200412 14655 Metaanalysis Comparing PlateletRich Plasma vs Hyaluronic Acid Injection 1427 7 Bourne RB Chesworth BM Davis AM Mahomed NN Charron KD Patient satisfaction total knee arthroplasty Who satisﬁed Clin Orthop Relat Res 201046815763 8 Bjordal JM Ljunggren AE Klovning A Slordal L including Nonsteroidal antiinﬂammatory drugs cyclooxygenase2 inhibitors osteoarthritic knee pain Metaanalysis randomised placebo controlled trials BMJ 20043297478131723 9 Harvey WF Hunter DJ The role analgesics intraarticular injections disease management Med Clin N Am 200993120111 10 Ju ni P Reichenbach S Trelle S et al Efﬁcacy safety intraarticular hylan hyaluronic acids osteoarthritis knee A randomized controlled trial Arthritis Rheum 2007561136109 11 Zhang HF Wang CG Li H Huang YT Li ZJ Intra articular plateletrich plasma versus hyaluronic acid treatment knee osteoarthritis A metaanaly sis Drug Des Devel Ther 20181244553 12 Cugat R Cusco X Seijas R et al Biologic enhance ment cartilage repair The role plateletrich plasma commercially available growth fac tors Arthroscopy 201531477783 13 Andia I Maffulli N Plateletrich plasma manag ing pain inﬂammation osteoarthritis Nat Rev Rheumatol 201391272130 14 Kon E Buda R Filardo G et al Plateletrich plasma Intraarticular knee injections produced favorable results degenerative cartilage lesions Knee Surg Sports Traumatol Arthrosc 20101844729 15 Sampson S Gerhardt M Mandelbaum B Platelet rich plasma injection grafts musculoskeletal inju ries A review Curr Rev Musculoskelet Med 20081 3416574 16 Foster TE Puskas BL Mandelbaum BR Gerhardt MB Rodeo SA Plateletrich plasma From basic sci ence clinical applications Am J Sports Med 2009 3711225972 17 Sundman EA Cole BJ Fortier LA Growth factor catabolic cytokine concentrations inﬂuenced cellular composition plateletrich plasma Am J Sports Med 20113910213540 18 LopezVidriero E Goulding KA Simon DA Sanchez M Johnson DH The use plateletrich plasma ar throscopy sports medicine Optimizing heal ing environment Arthroscopy 201026226978 19 Sanchez M Fiz N Guadilla J et al Intraosseous inﬁl tration plateletrich plasma severe knee osteo arthritis Arthrosc Tech 201436e7137 20 Rayegani SM Raeissadat SA Taheri MS et al Does intra articular platelet rich plasma injection improve function pain quality life patients oste oarthritis knee A randomized clinical trial Orthop Rev Pavia 2014631127 21 Vaquerizo V Plasencia MA Arribas I et al Comparison intraarticular injections plasma rich growth factors PRGFEndoret versus dur olane hyaluronic acid treatment patients symptomatic osteoarthritis A randomized controlled 201329 10163543 Arthroscopy trial 22 Filardo G Kon E Di Martino A et al Plateletrich plasma vs hyaluronic acid treat knee degenerative pathology Study design preliminary results randomized controlled trial BMC Musculoskelet Disord 20121322937 23 Dold AP Zywiel MG Taylor DW Dwyer T Theodoropoulos J Plateletrich plasma man agement articular cartilage pathology A systematic review Clin J Sport Med 20142413143 24 LaPrade CM James EW LaPrade RF Engebretsen L How evaluate outcomes use biolog ics knee J Knee Surg 20152813544 25 Kanchanatawan W Arirachakaran A Chaijenkij K et al Shortterm outcomes plateletrich plasma jection treatment osteoarthritis knee Knee Surg Sports Traumatol Arthrosc 201624 5166577 26 Ornetti P Nourissat G Berenbaum F et al Does plateletrich plasma role treatment os teoarthritis Joint Bone Spine 2016831316 27 Laudy ABM Bakker EWP Rekers M Moen MH Efﬁcacy plateletrich plasma injections osteoar thritis knee A systematic review meta analysis Brit J Sport Med 2015491065772 28 Paterson KL Nicholls M Bennell KL Bates D Intra articular injection photoactivated plateletrich plasma patients knee osteoarthritis A double blind study BMC randomized controlled pilot Musculoskelet Disord 2016176776 intrakneearticular 29 Li M Zhang C Ai Z et al Therapeutic effectiveness injection plateletrich plasma knee articular cartilage degeneration Chinese Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 20112511926 30 Cerza F Carni S Carcangiu A et al Comparison tween hyaluronic acid plateletrich plasma intra articular inﬁltration treatment gonarthrosis Am J Sports Med 2012401228227 31 Cole BJ Karas V Hussey K et al Hyaluronic acid versus plateletrich plasma A prospective double blind randomized controlled trial comparing clinical outcomes effects intraarticular biology treatment knee osteoarthritis Am J Sports Med 201745233946 32 Duymus TM Mutlu S Dernek B et al Choice intraarticular injection treatment knee osteoar thritis Plateletrich plasma hyaluronic acid ozone options Knee Surg Sports Traumatol Arthrosc 2017 25248592 33 Filardo G Di Matteo B Di Martino A et al Platelet rich plasma intraarticular knee injections A superiority viscosupplementation versus 1428 Han et al randomized controlled trial Am J Sports Med 2015 437157582 34 Gormeli G Gormeli CA Ataoglu B et al Multiple PRP injections effective single injec tions hyaluronic acid knees early osteoar placebo thritis A randomized controlled trial Knee Sports Traumatol Arthrosc 20172595865 doubleblind Surg 35 MontanezHeredia E Irizar S Huertas PJ et al Intra articular injections plateletrich plasma versus hy aluronic acid treatment osteoarthritic knee pain A randomized clinical trial context Spanish National Health Care System Int J Mol Sci 2016177106477 36 Raeissadat SA Rayegani SM Hassanabadi H et al Knee osteoarthritis injection choices Plateletrich plasma PRP versus hyaluronic acid oneyear ran domized clinical trial Clin Med Insights Arthritis Musculoskelet Disord 2015818 37 Sanchez M Fiz N Azofra J et al A randomized clini cal trial evaluating plasma rich growth factors PRGFEndoret versus hyaluronic acid short term treatment symptomatic knee osteoarthritis Arthroscopy 20122810708 38 Raeissadat SA Rayegani SM Ahangar AG et al Efﬁcacy intraarticular injection newly devel oped plasma rich growth factor PRGF versus hy aluronic acid pain function patients knee osteoarthritis A singleblinded randomized clin ical trial Clin Med Insights Arthritis Musculoskelet Disord 20171019 39 Louis ML Magalon J Jouve E et al Growth factors levels determine efﬁcacy platelets rich plasma injec tion knee osteoarthritis A randomized double blind noninferiority trial compared viscosupple mentation Arthroscopy 2018345153040 40 Stewart WF Ricci JA Chee E Morganstein D Lipton R Lost productive time cost com mon pain conditions US workforce JAMA 200329018244354 41 Gobbi A Lad D Karnatzikos G The effects peated intraarticular PRP injections clinical outcomes early osteoarthritis knee Knee 201523 Surg 821707 Traumatol Arthrosc Sports 42 Aigner T Kim HA Apoptosis cellular vitality cartilage degeneration osteoarthritic Issues Arthritis Rheum 2002468198696 43 Reitinger S Lepperdinger G Hyaluronan ready regeneration A minireview choice fuel Gerontology 2013591716 44 Bannuru RR Natov NS Dasi UR Schmid CH McAlindon TE Therapeutic trajectory following intraarticular hyaluronic acid injection knee osteo arthritismetaanalysis Osteoarthritis Cartilage 20111966119 45 Hunter DJ Lo GH The management osteoarthri tis An overview appropriate conservative treatment Rheum Dis Clin North Am 200834 3689712 46 Campbell J Bellamy N Gee T Differences systematic reviewsmetaanalyses hyaluronic acid hyaluronanhylan osteoarthritis knee Osteoarthritis Cartilage 20071512142436 47 Miller LE Block JE USapproved intraarticular hy aluronic acid injections safe effective patients knee osteoarthritis Systematic review metaanalysis randomized salinecontrolled trials Clin Med Insights Arthritis Musculoskelet Disord 201365763 48 Dagenais S Intraarticular hyaluronic acid viscosup plementation knee osteoarthritis Issues Emerg Health Technol 20069414 49 Kabiri A Esfandiari E Esmaeili A et al Plateletrich plasma application chondrogenesis Adv Biomed Res 2014313843 50 Levi D Horn S Tyszko S et al Intradiscal platelet rich plasma injection chronic discogenic low pain Preliminary results prospective trial Pain Med 201617101022 51 Lutz GE Increased nuclear T2 signal intensity improved function pain patient year intradiscal plateletrich plasma injection Pain Med 201718611979 52 Cole BJ Seroyer ST Filardo G Bajaj S Fortier LA Plateletrich plasma Where going Sports Health 20102320310 53 Patel S Dhillon MS Aggarwal S Marwaha N Jain A Treatment plateletrich plasma effec tive placebo knee osteoarthritis A prospec tive doubleblind randomized trial Am J Sports Med 201341235664 54 Meheux CJ McCulloch PC Lintner DM Varner KE Harris JD Efﬁcacy intraarticular plateletrich plasma injections knee osteoarthritis A systematic review Arthroscopy 2016323495505 55 Manferdini C Maumus M Gabusi E et al Adipose derived mesenchymal stem cells exert antiinﬂamma tory effects chondrocytes synoviocytes osteoarthritis patients prostaglandin E2 Arthritis Rheum 2013655127181 56 Vriesvan MM Narcisi R Kops N et al Chondrogenesis mesenchymal stem cells osteochondral environment mediated sub chondral bone Tissue Eng Part A 201420 122333 57 Lai LP Stitik TP Foye PM et al Use plateletrich plasma intraarticular knee injections osteoar thritis A systematic review Pm R 20157663748 58 Chang KV Hung CY Aliwarga F et al Comparative effectiveness plateletrich plasma injections treating knee joint cartilage degenerative pathology Metaanalysis Comparing PlateletRich Plasma vs Hyaluronic Acid Injection 1429 A systematic review metaanalysis Arch Phys Med Rehabil 201495356275 59 Filardo G Kon E Rofﬁ A et al Plateletrich plasma review intraarticular A systematic Why preclinical studies clinical evidence PRP joint degeneration Knee Surg Sports Traumatol Arthrosc 2015239245974